Tetra Bio Pharma (TSXV: TBP) announced this morning that it has newly created the role of President at the firm, appointing Sylvain Chrétien in the process. The move is being conducted to allow current CEO Guy Chamberland to be able to focus on the regulatory and development aspects of Tetra’s Caumz, Qixleef and HCC011 products.
Chrétien, who will report directly to Chamberland will largely be focused on that of investor relations as well as preparing the firm for the commercialization of Caumz and Qixleef. He will also be responsible for assisting the CFO with future financings conducted by the firm.
Sylvain has had a long career in the pharmaceutical industry, with his experience spanning over three decades within the field. Most recently, he served as a board member for Medexus Pharmaceutical, a firm focused on auto immune diseases and pediatrics. That company was formed following a three way merger between Medexus, Medac US, and Pediapharm, a company in which Chrétien founded in 2008.
I am honored to join Dr. Chamberland and the entire team of Tetra as they work to develop QIXEEF and CAUMZ for patients with advanced cancer pain. Helping businesses grow into fully integrated biopharmaceutical companies has been a cornerstone of my career and I’m thrilled to join the Tetra team as it moves forward in its mission in developing its cannabinoid drug derived therapies.
Sylvain Chrétien, President of Tetra Bio Pharma
Tetra Bio Pharma last traded at $0.43 on the TSX Venture.
Information for this briefing was found via Sedar and Tetra Bio-Pharma Inc. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.
Market Movers: Tetra Bio-Pharma
Cannabis adjacent pharma-co Tetra Bio-Pharma (TSXV: TBP) was the most active symbol on the TSX.V...